Immunity Project

Immunity Project Blog

The official record of the free HIV/AIDS vaccine.
 Have a question? Get in touch

Immunity Project Update on World AIDS Day 2015

Dear Friends, Over 36 million people are living with HIV and in 2014 over 2 million people died of AIDS. The fight is far from over. Our team is committed to continuing the development of the Immunity Project HIV vaccine prototype. We won’t stop until the eradication of HIV/AIDS is complete. We deeply apologize for […]

2014 End Of Year Update

Dear Friends, Happy Holidays and New Year.  With your help and unwavering support we achieved many major milestones in 2014.  Our accomplishments: Accepted into Y Combinator’s W14 batch and we presented at Y Combinator’s S14 demo day.  Thank you to the Y Combinator family for your advice, guidance and support. Reid presenting at Y Combinator’s demo […]

Peer reviewed article published in Vaccine

Over the weekend we learned that Vaccine published our article on eliciting cytotoxic T-lymphocyte responses from synthetic vectors containing one or two epitopes in a C57BL/6 mouse model using peptide-containing biodegradable microspheres and adjuvants.  In layperson terms, this article covers the work we did in partnership with Microsoft Research to show that our biodegradable microsphere based vaccine can elicit […]

Experiment Update #3

We’ve completed the human blood experiments described in our previous blog post.  Results: In vitro experiment: Overview Our vaccine is intended to “teach” the human immune system to act like that of an HIV controller (a person who has a natural immunity to the HIV virus).  The goal of our in vitro experiments is to successfully […]

Our Structure

Immunity Project is a non-profit initiative of Flow Pharma, Inc. dedicated to developing a free HIV vaccine. Flow Pharma, Inc. is a for-profit company that was founded in 2002 to develop drug delivery technologies. The company is focused on developing technologies related to manufacturing and formulation of biodegradable microspheres. The company has spent over $1 […]